My email to Dr. Kelly: Why no news on the NAS

My email to Dr. Kelly:

Why no news on the NASH 700mg results?

Surely the 1000 top line reports you are sending out to pharmaceutical companies are not based on the 350mg results?

Also, why do you not know whether your cancer trial subjects are still alive or not? Seems to me this would be pertinent to a BTD submission to the FDA.

Regards,
Xxx xxxxx
Shareholder


His response:

As you know, CytoDyn welcomes dialogue with shareholders, and we pride ourselves on the transparency we provide to investors and the market

However, as a public company, CytoDyn has “fair disclosure” obligations under Regulation FD, 17 CFR Part 243. The company is prohibited by federal law from disclosing material non-public information except in a public disclosure or under specifically enumerated conditions. Selective disclosure of material non-public information would violate our Regulation FD obligations and expose CytoDyn to potential litigation and regulatory actions.

We take seriously our obligation to protect material non-public information. Therefore we provide investors information in various public forums, including securities filings, press releases, and investor calls. We try to answer all questions on the investor’s conference call, but we can’t always promise every question will be answered despite our best intentions.

We invite you to submit additional questions in a publicly available forum, such as an investor call.

Best,

Scott